| Geri Connection | |
|
15644 Pomerado Rd Ste 202 Poway CA 92064-2434 | |
| (855) 839-8878 | |
| Not Available |
| Full Name | Geri Connection |
|---|---|
| Speciality | Family Medicine |
| Location | 15644 Pomerado Rd Ste 202, Poway, California |
| Authorized Official Name and Position | Teja Singh (OWNER/MD) |
| Authorized Official Contact | 8558398878 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Geri Connection 15644 Pomerado Rd Ste 202 Poway CA 92064-2434 Ph: () - | Geri Connection 15644 Pomerado Rd Ste 202 Poway CA 92064-2434 Ph: (855) 839-8878 |
| NPI Number | 1447976907 |
|---|---|
| Provider Enumeration Date | 10/17/2022 |
| Last Update Date | 01/04/2024 |
| Medicare PECOS PAC ID | 0446629059 |
|---|---|
| Medicare Enrollment ID | O20221202001861 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447976907 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | (* (Not Available)) | Primary |
| Provider Name | Teja Singh |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1205875606 PECOS PAC ID: 5193732030 Enrollment ID: I20060317000546 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Saleem Rajper |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1972533669 PECOS PAC ID: 7214068097 Enrollment ID: I20100622000746 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Laurie Eastwood Raher |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1629000104 PECOS PAC ID: 1759575525 Enrollment ID: I20101105000352 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Lindsey M Swan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1578712303 PECOS PAC ID: 5799841144 Enrollment ID: I20110914000615 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Meesha Puri |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1215103098 PECOS PAC ID: 0840442570 Enrollment ID: I20121204000223 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Maria P Sanchez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477739126 PECOS PAC ID: 1052552254 Enrollment ID: I20130731000409 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Serena C Arts |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1801881552 PECOS PAC ID: 9638108830 Enrollment ID: I20140728002590 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Manoj Saini |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1780082230 PECOS PAC ID: 2668792227 Enrollment ID: I20150521001234 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Heather Grace Moore |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1427426386 PECOS PAC ID: 7012217789 Enrollment ID: I20151202000545 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Gail Borbe Perry |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306369483 PECOS PAC ID: 4082973995 Enrollment ID: I20180123002457 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Dean Shehadeh |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1942688429 PECOS PAC ID: 9830421536 Enrollment ID: I20191030001041 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Dawn E Rose |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1134747595 PECOS PAC ID: 5092139287 Enrollment ID: I20200721002543 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Keena Nicole Harrison |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790334696 PECOS PAC ID: 1254747728 Enrollment ID: I20210308001627 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Mabel Anti |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104215631 PECOS PAC ID: 2163748013 Enrollment ID: I20210504001275 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Thai My Ngoc Nguyen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982206876 PECOS PAC ID: 5496156333 Enrollment ID: I20210629002019 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Theresa Timony |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1689818015 PECOS PAC ID: 9739455023 Enrollment ID: I20210825002639 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Shalaine E Reddic |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598438699 PECOS PAC ID: 1759787088 Enrollment ID: I20210910002154 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Lesley M Fung |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1518581917 PECOS PAC ID: 3274939475 Enrollment ID: I20210914002561 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Kim Dannenberg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1982172201 PECOS PAC ID: 0648668848 Enrollment ID: I20211020001559 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | My Van Luu Thi Nguyen |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598383689 PECOS PAC ID: 8921496910 Enrollment ID: I20211025000764 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Terry G Day |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1023517711 PECOS PAC ID: 9436176484 Enrollment ID: I20211108001152 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Katherine Barringer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255732228 PECOS PAC ID: 3072735125 Enrollment ID: I20211124001493 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Madison Palmer |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1336893254 PECOS PAC ID: 1658766050 Enrollment ID: I20220322001885 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Allison Breeann Leopold |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720379647 PECOS PAC ID: 3870751696 Enrollment ID: I20221013001503 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Oscar Brian Castillo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1396382206 PECOS PAC ID: 0446626345 Enrollment ID: I20221018001757 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Katherine Henson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083335525 PECOS PAC ID: 1153799135 Enrollment ID: I20221122003478 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Belen Anzaldo Wongk |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1639849284 PECOS PAC ID: 2264801810 Enrollment ID: I20221205000190 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Cindy Florentino |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1497330294 PECOS PAC ID: 5698144061 Enrollment ID: I20221206002521 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Ralaine Abdon |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1124699855 PECOS PAC ID: 8628447596 Enrollment ID: I20221215002048 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Michelle Erazo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1306556618 PECOS PAC ID: 8921478496 Enrollment ID: I20221227000525 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Christine Mari Johnson |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1790408045 PECOS PAC ID: 1355711540 Enrollment ID: I20230104002105 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Praise Him Tinungki |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1255056834 PECOS PAC ID: 4183094147 Enrollment ID: I20230109000712 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Jason Edwin Duryee |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1477268936 PECOS PAC ID: 9830562727 Enrollment ID: I20230223001192 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Tamara Selina Mcmillan |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881391480 PECOS PAC ID: 2365815131 Enrollment ID: I20230224001999 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Sharon Kepple |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1720460934 PECOS PAC ID: 0749653277 Enrollment ID: I20230303002323 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Danica Flores Trinidad |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275058448 PECOS PAC ID: 6204200637 Enrollment ID: I20230324002345 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Maruska Sanchez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1194261321 PECOS PAC ID: 1052785292 Enrollment ID: I20230329003154 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Ranita Hahm |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1881058188 PECOS PAC ID: 3375909609 Enrollment ID: I20230511002382 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Lauren Lowery |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1598492902 PECOS PAC ID: 5496111437 Enrollment ID: I20230518000200 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Semira Semino-asaro |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1821769340 PECOS PAC ID: 7012377666 Enrollment ID: I20230714001752 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Mariam C Ajmal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1104585090 PECOS PAC ID: 7719349646 Enrollment ID: I20230809003012 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Christopher Go |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083221568 PECOS PAC ID: 1052775095 Enrollment ID: I20230911000484 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Pardeep Kaur |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1083332076 PECOS PAC ID: 9537523444 Enrollment ID: I20230911004357 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Amber Lynn Brown |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1376201723 PECOS PAC ID: 7416301353 Enrollment ID: I20230927000925 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Pratibha Sehgal |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700571114 PECOS PAC ID: 5294180659 Enrollment ID: I20231005000766 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Macdaly Owens |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1912313602 PECOS PAC ID: 0749584084 Enrollment ID: I20231019001858 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Tzu Wei Lin |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1568243848 PECOS PAC ID: 4880040781 Enrollment ID: I20231030001511 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Brandon O'malley |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1952082646 PECOS PAC ID: 0648626481 Enrollment ID: I20231030003287 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Bethania Gonzalez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1922620657 PECOS PAC ID: 3971970054 Enrollment ID: I20231107000594 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Amanda Renee Layman |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1275308744 PECOS PAC ID: 6103274956 Enrollment ID: I20231205000229 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Leslie Rangel Gonzalez |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1346843653 PECOS PAC ID: 4183072945 Enrollment ID: I20231205000713 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Derrick Fian |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1417734658 PECOS PAC ID: 8820449432 Enrollment ID: I20240108006246 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Sunghui Kim |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1265210819 PECOS PAC ID: 0547611618 Enrollment ID: I20240112003185 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Kaori Sawada |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1013785609 PECOS PAC ID: 9931551918 Enrollment ID: I20240115001773 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Fei Wang |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1700535796 PECOS PAC ID: 0042662280 Enrollment ID: I20240123004050 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Maian Ngo |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1174208110 PECOS PAC ID: 1052764198 Enrollment ID: I20240125001454 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Taylor Connor |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1295413698 PECOS PAC ID: 2769835347 Enrollment ID: I20240131000096 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Joshuah Hinojosa |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1205603081 PECOS PAC ID: 0941653356 Enrollment ID: I20240201000093 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Victoria Eisenberg |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1447025739 PECOS PAC ID: 6709239023 Enrollment ID: I20240201004203 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Moorea Pugliese |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1972195386 PECOS PAC ID: 0840643128 Enrollment ID: I20240202001665 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
| Provider Name | Jasper Bernales Prima |
|---|---|
| Provider Type | Practitioner - Nurse Practitioner |
| Provider Identifiers | NPI Number: 1386289114 PECOS PAC ID: 7911340971 Enrollment ID: I20240206004003 |
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
News Archive
pSivida Corp, a leading drug delivery company that has developed two of the only three products approved by the FDA for the long-term, sustained release delivery of drug to treat chronic back of the eye disease, today reported the interim 18-month safety and efficacy results from the first human pharmacokinetic study (PK Study) of Iluvien®. The PK trial is being conducted by Alimera Sciences, the licensee for Iluvien.
Women who get most of their daily calcium from food have healthier bones than women whose calcium comes mainly from supplemental tablets, say researchers at Washington University School of Medicine in St. Louis.
Researchers at Mayo Clinic were awarded a $6.8 million, five-year federal grant from the National Institutes of Health to develop intelligent devices to track and treat abnormal brain activity in people with epilepsy. The grant, part of a presidential initiative aimed at revolutionizing the understanding of the human brain, is called Brain Research Through Advancing Innovative Neurotechnologies or the BRAIN Initiative.
Glaucoma-related highlights of today's scientific program of the 2008 Joint Meeting of the American Academy of Ophthalmology (Academy) and European Society of Ophthalmology (SOE) include a study that correlates optic nerve damage in glaucoma patients with carotid artery narrowing and potentially elevated risk for stroke, and a survey that looks at how the practice of fasting, common to the world's seven major religions, may affect patient compliance with treatment for glaucoma and other eye diseases.
› Verified 3 days ago
Neighborhood Healthcare - Gold Family Health Center Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 13010 Poway Road, Poway, CA 92064 Phone: 858-218-3000 | |
Virtue Medical Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15721 Pomerado Rd, Poway, CA 92064 Phone: 949-973-3704 Fax: 760-400-4075 | |
North County Geriatrics Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 15611 Pomerado Rd, Suite 575, Poway, CA 92064 Phone: 858-675-3100 Fax: 858-487-4736 | |
Vituity Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15615 Pomerado Rd, Poway, CA 92064 Phone: 858-613-4000 Fax: 858-613-4217 | |
Ficaremed Pc Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 15644 Pomerado Rd Ste 100, Poway, CA 92064 Phone: 858-485-5111 Fax: 858-485-6747 | |
San Diego Mobile Physicians Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 12285 Scripps Poway Pkwy Ste 103, Poway, CA 92064 Phone: 760-622-2773 Fax: 858-842-1168 | |
Sumer Inc. Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 15644 Pomerado Rd Ste 401, Poway, CA 92064 Phone: 858-648-0213 Fax: 858-216-1980 |